{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T18:22:00Z","timestamp":1784398920788,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.bbmt.2019.09.001","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T19:41:17Z","timestamp":1567712477000},"page":"285-291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms"],"prefix":"10.1016","volume":"26","author":[{"given":"Yi-Geng","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Dong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Xian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hua","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao-Ling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Ming","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Ling","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Ling","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Zhou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Er-Lie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Zhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2019.09.001_bib0001","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0145-2126(02)00098-X","article-title":"The myelodysplastic syndrome(s): a perspective and review highlighting current controversies","volume":"27","author":"Steensma","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0002","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccr.2004.12.004","article-title":"Focus on myeloproliferative diseases and myelodysplastic syndromes","volume":"6","author":"Van Etten","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0003","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1586\/eci.12.18","article-title":"Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade","volume":"8","author":"Karoopongse","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0004","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.bbmt.2015.07.037","article-title":"Management of myelodysplastic syndrome relapsing after allogeneic hematopoietic stem cell transplantation: a study by the French Society of Bone Marrow Transplantation and Cell Therapies","volume":"22","author":"Gui\u00e8ze","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0005","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1182\/blood-2006-02-005702","article-title":"Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics","volume":"108","author":"DeAngelo","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0006","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.bbmt.2018.04.025","volume":"24","author":"Nemecek","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0007","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/bmt.2015.295","article-title":"Safety of ruxolitinib therapy prior to allogeneic hematopoietic stem-cell transplantation for myeloproliferative neoplasms","volume":"51","author":"Hanif","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0008","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.14694\/EdBook_AM.2015.35.e398","article-title":"Myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including allogeneic hematopoietic stem cell transplantation","author":"Odenike","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0009","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1182\/blood-2003-03-0687","article-title":"Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2\u2032-deoxycytidine (decitabine) in hematopoietic malignancies","volume":"103","author":"Issa","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0010","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/cncr.11543","article-title":"Results of decitabine (5-aza-2\u2032deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0011","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2003-05-1738","article-title":"Effects of 5-aza-2\u2032-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease","volume":"102","author":"Saunthararajah","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0012","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/petr.12805","article-title":"Decitabine prior to salvaged unrelated cord blood transplantation for refractory or relapsed childhood acute leukemia","volume":"20","author":"Zhou","year":"2016","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0013","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/ijc.25635","article-title":"Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation","volume":"128","author":"Schmiedel","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0014","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1182\/blood-2014-09-599993","article-title":"Haploidentical hematopoietic transplantation from KIR ligand-mismatched donors with activating KIRs reduces nonrelapse mortality","volume":"125","author":"Mancusi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0015","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.bbmt.2016.02.003","article-title":"Addition of 10-day decitabine to fludarabine\/total body irradiation conditioning is feasible and induces tumor-associated antigen-specific T cell responses","volume":"22","author":"Cruijsen","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0016","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s12325-015-0263-8","article-title":"Decitabine for treatment of myelodysplastic syndromes in Chinese patients: an open-label, phase-3b study","volume":"32","author":"Wu","year":"2015","journal-title":"Adv Ther"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0017","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11096-014-0036-5","article-title":"A modified busulfan and cyclophosphamide preparative regimen for allogeneic transplantation in myeloid malignancies","volume":"37","author":"Cai","year":"2015","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0018","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.bbmt.2012.10.002","article-title":"Impact of pretransplantation risk factors on post transplantation outcome of patients with acute myeloid leukemia in remission after haploidentical hematopoietic stem cell transplantation","volume":"19","author":"Wang","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0019","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0020","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0021","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2016.71.0806","article-title":"Clinical implications of genetic mutations in myelodysplastic syndrome","volume":"35","author":"Kennedy","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0022","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41408-018-0074-7","article-title":"Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome","volume":"8","author":"Hou","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0023","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0024","doi-asserted-by":"crossref","first-page":"9714","DOI":"10.18632\/oncotarget.23882","article-title":"Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic\/myeloproliferative neoplasms","volume":"9","author":"Montalban-Bravo","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0025","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0026","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/bmt.2017.229","article-title":"Myeloablative conditioning regimens with combined of haploidentical and cord blood transplantation for myelodysplastic syndrome patients","volume":"53","author":"Ke","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0027","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/bmt.2009.351","article-title":"HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome","volume":"45","author":"Chen","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0028","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.bbmt.2010.08.023","article-title":"Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison","volume":"17","author":"Wang","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0029","first-page":"467","article-title":"[Decitabine-based conditioning regimen is feasible and effective in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia]","volume":"40","author":"Zhao","year":"2019","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0030","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1182\/blood-2006-08-041145","article-title":"Low-dose decitabine and high-risk MDS","volume":"108","author":"Raza","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0031","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood-2008-07-171926","article-title":"Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia","volume":"113","author":"Cooley","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0032","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.4049\/jimmunol.1302517","article-title":"Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia","volume":"192","author":"Cooley","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0033","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0034","doi-asserted-by":"crossref","first-page":"12840","DOI":"10.18632\/oncotarget.7326","article-title":"Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy","volume":"7","author":"Srivastava","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbmt.2019.09.001_bib0035","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","article-title":"Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia","volume":"116","author":"Goodyear","year":"2010","journal-title":"Blood"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119305695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119305695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:08:43Z","timestamp":1761059323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879119305695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1083879119305695"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.09.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736572763.793566318","asserted-by":"object"}]},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conditioning Regimen of 5-Day Decitabine Administration for Allogeneic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome and Myeloproliferative Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.09.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}